CO15 A Matching-Adjusted Indirect Comparison of Efgartigimod Versus Ravulizumab for Generalized Myasthenia Gravis
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.096
https://www.valueinhealthjournal.com/article/S1098-3015(22)02300-2/fulltext
Title :
CO15 A Matching-Adjusted Indirect Comparison of Efgartigimod Versus Ravulizumab for Generalized Myasthenia Gravis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02300-2&doi=10.1016/j.jval.2022.09.096
First page :
Section Title :
Open access? :
No
Section Order :
10516